RHOA and lung cancer: With regard to tumours, PHF5A is overexpressed in lung cancer, breast cancer, colorectal cancer and hepatocellular carcinoma [26–29] and promotes malignant tumour biological progression associated with the NF-κB pathway [29], RhoA/ROCK pathway [30], and activation of HDAC8 [31].